Yann Mazabraud - Apr 14, 2023 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
EVP, Head of International
Signature
/s/ Hunter Smith, Attorney-in-Fact for Yann Mazabraud
Stock symbol
RYTM
Transactions as of
Apr 14, 2023
Transactions value $
$0
Form type
4
Date filed
4/18/2023, 05:16 PM
Previous filing
Feb 16, 2023
Next filing
Feb 13, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Restricted Stock Units Disposed to Issuer $0 -41.5K -100% $0.00* 0 Apr 14, 2023 Common Stock 41.5K Direct F1, F2, F3
transaction RYTM Restricted Stock Units Award $0 +41.5K $0.00 41.5K Apr 14, 2023 Common Stock 41.5K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2 The restricted stock units were rescinded and cancelled by mutual agreement of the reporting person and Issuer. The reporting person received French-qualified restricted stock units on April 14, 2023 as consideration for the recission and cancellation of the restricted stock previously received on February 1, 2023.
F3 The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date.
F4 The restricted stock units vest as to 25% of the total shares on each of April 14, 2024, April 14, 2025, April 14, 2026 and April 14, 2027. The restricted stock units have no expiration date.